Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
57 participants
INTERVENTIONAL
2024-11-01
2026-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reconstructive Therapy for Peri-implantitis Using Tuberosity Bone with or Without Electrolytic Cleaning: a Randomized Clinical Trial
NCT06708247
Evaluation of Fractalkine and Its Receptor in Peri-implantitis
NCT06685523
Treatment of Peri-implant Mucositis and Supportive Peri-implant Therapy
NCT06137846
L-PRF for Increasing Keratinised Mucosa Around Implants
NCT03190226
Efficacy of Non-surgical and Surgical Surface Decontamination Methods on Peri-implantitis-affected Implants
NCT06430268
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Prospective, in which participants will be recruited and then followed up throughout a specified period of time.
* Randomized, parallel designed, concurrent controlled trial with participants randomly allocated to either control or test groups.
* Single-blinded as the outcome accessors will be blinded to the intervention.
Materials and Methods:
Patients attending Dubai Dental Hospital and requiring treatment of peri-implantitis will be invited to take part in this randomized controlled trial based on the following inclusion and exclusion criteria:
Inclusion criteria:
* Aged 18 or over.
* Require treatment of peri-implantitis (defined as the presence of bleeding and/or suppuration on gentle probing, probing depths of ≥ 6 mm, presence of bone loss beyond crestal bone level changes resulting from initial bone remodeling).
* Screw retained implant crown.
* Good compliance and commitment to attend follow-up review appointments.
* Willing to provide informed consent.
Exclusion criteria
* History of surgical therapy of peri-implantitis.
* Peri-implant defects indicated for regenerative procedure (i.e. contained bony defect).
* Cement retained implant crown.
* Systemic/local antibiotics during the previous 6 months.
* Bone metabolic disease and/or taking medications that affect bone metabolism.
* History of malignancy, radiotherapy or chemotherapy.
* Pregnant or lactating women.
* Smokers
The study will be conducted following the ethical standards of the Declaration of Helsinki in 1975, as revised in 2013 and the CONSORT statement will be used as a guideline in reporting this study.
Randomization, allocation concealment and blinding:
The participants will be randomly allocated to three equally sized groups using computer-generated numbers:
Control group (C): Conventional open flap debridement Test group 1 (T1): Open flap debridement using (GalvoSurge® - Straumann) Test group 2 (T2): Open flap debridement using (GalvoSurge® - Straumann) combined with L-PRF application
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group (C): Conventional open flap debridement
Conventional open flap debridement
Control group (C)
Conventional open flap debridement
Test group 1 (T1): Open flap debridement using electrolysis decontamination
Open flap debridement using (GalvoSurge® - Straumann)
Test group 1 (T1)
Test group 1 (T1): Open flap debridement using electrolysis decontamination
Test group 2 (T2): Open flap debridement using electrolysis decontamination combined with L-PRF
Open flap debridement using (GalvoSurge® - Straumann) combined with L-PRF application
Test group 2 (T2)
Test group 2 (T2): Open flap debridement using electrolysis decontamination combined with L-PRF application
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Test group 1 (T1)
Test group 1 (T1): Open flap debridement using electrolysis decontamination
Test group 2 (T2)
Test group 2 (T2): Open flap debridement using electrolysis decontamination combined with L-PRF application
Control group (C)
Conventional open flap debridement
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Require treatment of peri-implantitis (defined as the presence of bleeding and/or suppuration on gentle probing, probing depths of ≥ 6 mm, presence of bone loss beyond crestal bone level changes resulting from initial bone remodeling).
* Screw retained implant crown.
* Good compliance and commitment to attend follow-up review appointments.
* Willing to provide informed consent.
Exclusion Criteria
* Peri-implant defects indicated for regenerative procedure (i.e. contained bony defect).
* Cement retained implant crown.
* Systemic/local antibiotics during the previous 6 months.
* Bone metabolic disease and/or taking medications that affect bone metabolism.
* History of malignancy, radiotherapy or chemotherapy.
* Pregnant or lactating women.
* Smokers
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abeer Hakam
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abeer Hakam
Assistant professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Hamzacebi B, Oduncuoglu B, Alaaddinoglu EE. Treatment of Peri-implant Bone Defects with Platelet-Rich Fibrin. Int J Periodontics Restorative Dent. 2015 May-Jun;35(3):415-22. doi: 10.11607/prd.1861.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MBRU IRB-2024-563
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.